Brief: Heidelberg Pharma Announces Conclusion Of License Agreement With Partner Takeda To Develop An Antibody Targeted Amanitin Conjugate

Heidelberg Pharma AG

09/09/2022 17:05

Sept 9 (Reuters) - Heidelberg Pharma AG  HPHA.DE :
    * DGAP-ADHOC: HEIDELBERG PHARMA ANNOUNCES CONCLUSION OF
LICENSE
AGREEMENT WITH PARTNER TAKEDA TO DEVELOP AN ANTIBODY TARGETED
AMANITIN CONJUGATE
    * CO SUBSIDIARY, TAKEDA SIGNED LICENSE AGREEMENT GRANTING
TAKEDA
AN EXCLUSIVE LICENSE TO COMMERCIALLY DEVELOP AN ANTIBODY
TARGETED AMANITIN CONJUGATE
    * CO RECEIVES AN UNDISCLOSED MILESTONE PAYMENT IN RETURN;
ELIGIBLE
TO RECEIVE POTENTIAL FUTURE CLINICAL DEVELOPMENT MILESTONE
PAYMENTS

Source text for Eikon:  ID:nEQ1ZPPb9a 
Further company coverage:  HPHA.DE 

 ((reuters.briefs@thomsonreuters.com;))